Chronic urticaria patients are interested in apps to monitor their disease activity and control: A UCARE CURICT analysis

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Standard

Chronic urticaria patients are interested in apps to monitor their disease activity and control : A UCARE CURICT analysis. / Cherrez-Ojeda, Ivan; Vanegas, Emanuel; Cherrez, Annia; Felix, Miguel; Weller, Karsten; Magerl, Markus; Maurer, Rasmus Robin; Mata, Valeria L.; Kasperska-Zajac, Alicja; Sikora, Agnieszka; Fomina, Daria; Kovalkova, Elena; Godse, Kiran; Rao, Nimmagadda Dheeraj; Khoshkhui, Maryam; Rastgoo, Sahar; Criado, Roberta F.J.; Abuzakouk, Mohamed; Grandon, Deepa; Van Doorn, Martijn B.A.; Rodrigues Valle, Solange Oliveira; De Souza Lima, Eduardo Magalhães; Thomsen, Simon Francis; Ramón, German D.; Matos Benavides, Edgar E.; Bauer, Andrea; Giménez-Arnau, Ana M.; Kocatürk, Emek; Guillet, Carole; Larco, Jose Ignacio; Zhao, Zuo Tao; Makris, Michael; Ritchie, Carla; Xepapadaki, Paraskevi; Ensina, Luis Felipe; Cherrez, Sofia; Maurer, Marcus.

I: Clinical and Translational Allergy, Bind 11, Nr. 10, e12089, 2021.

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Harvard

Cherrez-Ojeda, I, Vanegas, E, Cherrez, A, Felix, M, Weller, K, Magerl, M, Maurer, RR, Mata, VL, Kasperska-Zajac, A, Sikora, A, Fomina, D, Kovalkova, E, Godse, K, Rao, ND, Khoshkhui, M, Rastgoo, S, Criado, RFJ, Abuzakouk, M, Grandon, D, Van Doorn, MBA, Rodrigues Valle, SO, De Souza Lima, EM, Thomsen, SF, Ramón, GD, Matos Benavides, EE, Bauer, A, Giménez-Arnau, AM, Kocatürk, E, Guillet, C, Larco, JI, Zhao, ZT, Makris, M, Ritchie, C, Xepapadaki, P, Ensina, LF, Cherrez, S & Maurer, M 2021, 'Chronic urticaria patients are interested in apps to monitor their disease activity and control: A UCARE CURICT analysis', Clinical and Translational Allergy, bind 11, nr. 10, e12089. https://doi.org/10.1002/clt2.12089

APA

Cherrez-Ojeda, I., Vanegas, E., Cherrez, A., Felix, M., Weller, K., Magerl, M., Maurer, R. R., Mata, V. L., Kasperska-Zajac, A., Sikora, A., Fomina, D., Kovalkova, E., Godse, K., Rao, N. D., Khoshkhui, M., Rastgoo, S., Criado, R. F. J., Abuzakouk, M., Grandon, D., ... Maurer, M. (2021). Chronic urticaria patients are interested in apps to monitor their disease activity and control: A UCARE CURICT analysis. Clinical and Translational Allergy, 11(10), [e12089]. https://doi.org/10.1002/clt2.12089

Vancouver

Cherrez-Ojeda I, Vanegas E, Cherrez A, Felix M, Weller K, Magerl M o.a. Chronic urticaria patients are interested in apps to monitor their disease activity and control: A UCARE CURICT analysis. Clinical and Translational Allergy. 2021;11(10). e12089. https://doi.org/10.1002/clt2.12089

Author

Cherrez-Ojeda, Ivan ; Vanegas, Emanuel ; Cherrez, Annia ; Felix, Miguel ; Weller, Karsten ; Magerl, Markus ; Maurer, Rasmus Robin ; Mata, Valeria L. ; Kasperska-Zajac, Alicja ; Sikora, Agnieszka ; Fomina, Daria ; Kovalkova, Elena ; Godse, Kiran ; Rao, Nimmagadda Dheeraj ; Khoshkhui, Maryam ; Rastgoo, Sahar ; Criado, Roberta F.J. ; Abuzakouk, Mohamed ; Grandon, Deepa ; Van Doorn, Martijn B.A. ; Rodrigues Valle, Solange Oliveira ; De Souza Lima, Eduardo Magalhães ; Thomsen, Simon Francis ; Ramón, German D. ; Matos Benavides, Edgar E. ; Bauer, Andrea ; Giménez-Arnau, Ana M. ; Kocatürk, Emek ; Guillet, Carole ; Larco, Jose Ignacio ; Zhao, Zuo Tao ; Makris, Michael ; Ritchie, Carla ; Xepapadaki, Paraskevi ; Ensina, Luis Felipe ; Cherrez, Sofia ; Maurer, Marcus. / Chronic urticaria patients are interested in apps to monitor their disease activity and control : A UCARE CURICT analysis. I: Clinical and Translational Allergy. 2021 ; Bind 11, Nr. 10.

Bibtex

@article{da455d60a4a34ceabbca90e953741b20,
title = "Chronic urticaria patients are interested in apps to monitor their disease activity and control: A UCARE CURICT analysis",
abstract = "Background: Information/communication technologies such as mobile phone applications (apps) would enable chronic urticaria (CU) patients to self-evaluate their disease activity and control. Yet, recently Ant{\'o} et al (2021) reported a global paucity of such apps for patients with CU. In this analysis, we assessed patient interest in using apps to monitor CU disease activity and control using questions from the chronic urticaria information and communication technologies (CURICT) study. Methods: The methodology for CURICT has been reported. Briefly, a 23-item questionnaire was completed by 1841 CU patients from 17 UCAREs across 17 countries. Here, we analyzed patient responses to the CURICT questions on the use of apps for urticaria-related purposes. Results: As previously published, the majority of respondents had chronic spontaneous urticaria (CSU; 63%; 18% chronic inducible urticaria (CIndU) [CIndu]; 19% with both), were female (70%) and in urban areas (75%). Over half of patients were very/extremely interested in an app to monitor disease activity (51%) and control (53%), while only ∼1/10 were not. Patients with both urticaria types versus those with CSU only (odds ratio [OR], 1.36 [1.03–1.79]) and females versus males (OR [95% CI], 1.47 [1.17–1.85]) were more likely to be very to extremely interested in an app to assess disease control. Conclusions: Overall, half of the patients with CU were very to extremely interested in using an app to assess their disease activity and control. Development of well-designed apps, specific to disease types (CSU, CIndU, CSU + CIndU, etc), validated by experts across platforms would help improve the management and possibly outcomes of CU treatment while providing important patient information to be used in future research.",
keywords = "apps, chronische induzierbare urtikaria, chronische spontane urtikaria, chronische urtikaria, UCARE",
author = "Ivan Cherrez-Ojeda and Emanuel Vanegas and Annia Cherrez and Miguel Felix and Karsten Weller and Markus Magerl and Maurer, {Rasmus Robin} and Mata, {Valeria L.} and Alicja Kasperska-Zajac and Agnieszka Sikora and Daria Fomina and Elena Kovalkova and Kiran Godse and Rao, {Nimmagadda Dheeraj} and Maryam Khoshkhui and Sahar Rastgoo and Criado, {Roberta F.J.} and Mohamed Abuzakouk and Deepa Grandon and {Van Doorn}, {Martijn B.A.} and {Rodrigues Valle}, {Solange Oliveira} and {De Souza Lima}, {Eduardo Magalh{\~a}es} and Thomsen, {Simon Francis} and Ram{\'o}n, {German D.} and {Matos Benavides}, {Edgar E.} and Andrea Bauer and Gim{\'e}nez-Arnau, {Ana M.} and Emek Kocat{\"u}rk and Carole Guillet and Larco, {Jose Ignacio} and Zhao, {Zuo Tao} and Michael Makris and Carla Ritchie and Paraskevi Xepapadaki and Ensina, {Luis Felipe} and Sofia Cherrez and Marcus Maurer",
note = "Publisher Copyright: {\textcopyright} 2021 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.",
year = "2021",
doi = "10.1002/clt2.12089",
language = "English",
volume = "11",
journal = "Clinical and Translational Allergy",
issn = "2045-7022",
publisher = "BioMed Central Ltd.",
number = "10",

}

RIS

TY - JOUR

T1 - Chronic urticaria patients are interested in apps to monitor their disease activity and control

T2 - A UCARE CURICT analysis

AU - Cherrez-Ojeda, Ivan

AU - Vanegas, Emanuel

AU - Cherrez, Annia

AU - Felix, Miguel

AU - Weller, Karsten

AU - Magerl, Markus

AU - Maurer, Rasmus Robin

AU - Mata, Valeria L.

AU - Kasperska-Zajac, Alicja

AU - Sikora, Agnieszka

AU - Fomina, Daria

AU - Kovalkova, Elena

AU - Godse, Kiran

AU - Rao, Nimmagadda Dheeraj

AU - Khoshkhui, Maryam

AU - Rastgoo, Sahar

AU - Criado, Roberta F.J.

AU - Abuzakouk, Mohamed

AU - Grandon, Deepa

AU - Van Doorn, Martijn B.A.

AU - Rodrigues Valle, Solange Oliveira

AU - De Souza Lima, Eduardo Magalhães

AU - Thomsen, Simon Francis

AU - Ramón, German D.

AU - Matos Benavides, Edgar E.

AU - Bauer, Andrea

AU - Giménez-Arnau, Ana M.

AU - Kocatürk, Emek

AU - Guillet, Carole

AU - Larco, Jose Ignacio

AU - Zhao, Zuo Tao

AU - Makris, Michael

AU - Ritchie, Carla

AU - Xepapadaki, Paraskevi

AU - Ensina, Luis Felipe

AU - Cherrez, Sofia

AU - Maurer, Marcus

N1 - Publisher Copyright: © 2021 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.

PY - 2021

Y1 - 2021

N2 - Background: Information/communication technologies such as mobile phone applications (apps) would enable chronic urticaria (CU) patients to self-evaluate their disease activity and control. Yet, recently Antó et al (2021) reported a global paucity of such apps for patients with CU. In this analysis, we assessed patient interest in using apps to monitor CU disease activity and control using questions from the chronic urticaria information and communication technologies (CURICT) study. Methods: The methodology for CURICT has been reported. Briefly, a 23-item questionnaire was completed by 1841 CU patients from 17 UCAREs across 17 countries. Here, we analyzed patient responses to the CURICT questions on the use of apps for urticaria-related purposes. Results: As previously published, the majority of respondents had chronic spontaneous urticaria (CSU; 63%; 18% chronic inducible urticaria (CIndU) [CIndu]; 19% with both), were female (70%) and in urban areas (75%). Over half of patients were very/extremely interested in an app to monitor disease activity (51%) and control (53%), while only ∼1/10 were not. Patients with both urticaria types versus those with CSU only (odds ratio [OR], 1.36 [1.03–1.79]) and females versus males (OR [95% CI], 1.47 [1.17–1.85]) were more likely to be very to extremely interested in an app to assess disease control. Conclusions: Overall, half of the patients with CU were very to extremely interested in using an app to assess their disease activity and control. Development of well-designed apps, specific to disease types (CSU, CIndU, CSU + CIndU, etc), validated by experts across platforms would help improve the management and possibly outcomes of CU treatment while providing important patient information to be used in future research.

AB - Background: Information/communication technologies such as mobile phone applications (apps) would enable chronic urticaria (CU) patients to self-evaluate their disease activity and control. Yet, recently Antó et al (2021) reported a global paucity of such apps for patients with CU. In this analysis, we assessed patient interest in using apps to monitor CU disease activity and control using questions from the chronic urticaria information and communication technologies (CURICT) study. Methods: The methodology for CURICT has been reported. Briefly, a 23-item questionnaire was completed by 1841 CU patients from 17 UCAREs across 17 countries. Here, we analyzed patient responses to the CURICT questions on the use of apps for urticaria-related purposes. Results: As previously published, the majority of respondents had chronic spontaneous urticaria (CSU; 63%; 18% chronic inducible urticaria (CIndU) [CIndu]; 19% with both), were female (70%) and in urban areas (75%). Over half of patients were very/extremely interested in an app to monitor disease activity (51%) and control (53%), while only ∼1/10 were not. Patients with both urticaria types versus those with CSU only (odds ratio [OR], 1.36 [1.03–1.79]) and females versus males (OR [95% CI], 1.47 [1.17–1.85]) were more likely to be very to extremely interested in an app to assess disease control. Conclusions: Overall, half of the patients with CU were very to extremely interested in using an app to assess their disease activity and control. Development of well-designed apps, specific to disease types (CSU, CIndU, CSU + CIndU, etc), validated by experts across platforms would help improve the management and possibly outcomes of CU treatment while providing important patient information to be used in future research.

KW - apps

KW - chronische induzierbare urtikaria

KW - chronische spontane urtikaria

KW - chronische urtikaria

KW - UCARE

UR - http://www.scopus.com/inward/record.url?scp=85122005119&partnerID=8YFLogxK

U2 - 10.1002/clt2.12089

DO - 10.1002/clt2.12089

M3 - Journal article

C2 - 34962721

AN - SCOPUS:85122005119

VL - 11

JO - Clinical and Translational Allergy

JF - Clinical and Translational Allergy

SN - 2045-7022

IS - 10

M1 - e12089

ER -

ID: 290534330